Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Application based on results from the TROPION-Breast01 Phase III trial
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
The validations confirm the completion of the applications and commence the scientific review process
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
